Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 97, showing 5 Applications out of 482 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/23/01/06   FENHANCE
    A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS         CSF BIOMARKER SUBSTUDY ASSOCIATED WITH A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY (GN41851) TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS        
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View

107.

ECCT/23/01/05   IMPALA Study
    Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

108.

ECCT/23/01/04   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Lucas Tina Otieno
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
4. Kenyatta National Hospital (Nairobi City county)
5. Ahero Clinical Trials Unit, (Kisumu county)
6. KEMRI CCR – BUTERE SITE (Kakamega county)
 
View

109.

ECCT/23/01/03   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Githanga Githanga Nyokabi
Site(s) in Kenya
1. Gertrude\'s Children Hospital (Nairobi City county)
2. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View

110.

ECCT/23/01/02   PRAISE
    An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)   
Principal Investigator(s)
1. Ogutu Bernhards Ragama
Site(s) in Kenya
1. Kondele Children\'s Hospital Center for Clinical Research (CCR), (Kisumu county)
2. Gertrude\'s Children Hospital (Nairobi City county)
3. KEMRI/CRDR Kemri Clinical Research Annex Siaya County Referral Hospital Grounds, (Siaya county)
4. Kombewa CRC (Kisumu county)
 
View